- Home
- ANGO vs DRUG Comparison
ANGO vs DRUG Comparison
Compare ANGO & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANGO
- DRUG
- Stock Information
- Founded
- ANGO 1988
- DRUG 2019
- Country
- ANGO United States
- DRUG United States
- Employees
- ANGO N/A
- DRUG N/A
- Industry
- ANGO Medical/Dental Instruments
- DRUG Pharmaceuticals and Biotechnology
- Sector
- ANGO Health Care
- DRUG Health Care
- Exchange
- ANGO Nasdaq
- DRUG Nasdaq
- Market Cap
- ANGO 400.8M
- DRUG 345.6M
- IPO Year
- ANGO 2004
- DRUG N/A
- Fundamental
- Price
- ANGO $11.05
- DRUG $63.49
- Analyst Decision
- ANGO Strong Buy
- DRUG Strong Buy
- Analyst Count
- ANGO 3
- DRUG 9
- Target Price
- ANGO $19.33
- DRUG $81.67
- AVG Volume (30 Days)
- ANGO 587.8K
- DRUG 97.1K
- Earning Date
- ANGO 10-02-2025
- DRUG 08-11-2025
- Dividend Yield
- ANGO N/A
- DRUG N/A
- EPS Growth
- ANGO N/A
- DRUG N/A
- EPS
- ANGO N/A
- DRUG N/A
- Revenue
- ANGO $300,718,000.00
- DRUG N/A
- Revenue This Year
- ANGO $7.42
- DRUG N/A
- Revenue Next Year
- ANGO $6.36
- DRUG N/A
- P/E Ratio
- ANGO N/A
- DRUG N/A
- Revenue Growth
- ANGO 2.73
- DRUG N/A
- 52 Week Low
- ANGO $5.99
- DRUG $1.04
- 52 Week High
- ANGO $13.50
- DRUG $79.02
- Technical
- Relative Strength Index (RSI)
- ANGO 55.56
- DRUG 67.26
- Support Level
- ANGO $10.78
- DRUG $48.94
- Resistance Level
- ANGO $12.76
- DRUG $61.72
- Average True Range (ATR)
- ANGO 0.52
- DRUG 4.47
- MACD
- ANGO -0.05
- DRUG 0.30
- Stochastic Oscillator
- ANGO 27.12
- DRUG 83.18
About ANGO AngioDynamics Inc.
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.